The France-based clinical-stage biotech, known for its pipeline of gene therapies targeting hearing loss, has confidentially submitted a draft registration statement to the SEC as it evaluates a potential listing on a US national exchange.
Sensorion, a clinical-stage biotechnology company focused on developing therapies to restore hearing and treat and prevent hearing loss disorders, has confidentially submitted a draft registration statement on Form F-1 to the US Securities and Exchange Commission (SEC).
The Montpellier, France-based company — which also maintains a presence in Cambridge, Mass. — said the confidential submission is a preliminary step in its evaluation of a potential US initial public offering (IPO) of its ordinary shares, including in the form of American Depositary Shares (ADSs), and the listing of such ADSs on a US national exchange, subject to market and other conditions.
The move signals a potential milestone for a company that has been advancing a pipeline of inner ear therapeutics, including gene therapy candidates targeting genetic forms of hearing loss. Sensorion’s SENS-601 program — its investigational gene therapy for GJB2-related hearing loss — received French regulatory approval to initiate the HearConnex clinical trial earlier this year.
Sensorion describes itself as having built a unique R&D technology platform to expand its understanding of the pathophysiology and etiology of inner ear-related diseases, enabling it to select targets and mechanisms of action for drug candidates.
No terms for a potential offering — including share price, number of shares, or timing — have been disclosed. The company noted that the announcement does not constitute an offer to sell or solicitation of an offer to buy securities.
Sensorion trades on the Euronext Growth Paris exchange under the ticker ALSEN (ISIN: FR001401A9Z0). A US listing, if completed, would expand the company’s access to American capital markets as it continues to advance its hearing loss pipeline through clinical development.
